{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:22:03Z","timestamp":1794604923570,"version":"4.9.1"},"reference-count":113,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008246","name":"School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007155","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ijantimicag.2018.11.011","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T04:49:47Z","timestamp":1542948587000},"page":"234-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-9812","authenticated-orcid":false,"given":"Aaron J.","family":"Heffernan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4061-2063","authenticated-orcid":false,"given":"Fekade B.","family":"Sime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9803-9701","authenticated-orcid":false,"given":"Jayesh","family":"Dhanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4512-6443","authenticated-orcid":false,"given":"David","family":"Ellwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3174-9834","authenticated-orcid":false,"given":"Keith","family":"Grimwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0001","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/cid\/ciw504","article-title":"Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0002","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1473-3099(13)70081-1","article-title":"Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies","volume":"13","author":"Melsen","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008924","article-title":"Incidence of ventilator-associated pneumonia in Australasian intensive care units: use of a consensus-developed clinical surveillance checklist in a multisite prospective audit","author":"Elliott","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0004","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.297.14.1583","article-title":"Does this patient have ventilator-associated pneumonia?","volume":"297","author":"Klompas","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/MCP.0000000000000042","article-title":"Aetiology of hospital-acquired pneumonia and trends in antimicrobial resistance","volume":"20","author":"Enne","year":"2014","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0006","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/SHK.0b013e3181cc0418","article-title":"Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis","volume":"33","author":"Siempos","year":"2010","journal-title":"Shock"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0007","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/01.CCM.0000249826.81273.E4","article-title":"Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia","volume":"35","author":"Combes","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0008","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00134-009-1417-4","article-title":"Bacterial ventilator-associated pneumonia: bronchoalveolar lavage results are not influenced by dilution","volume":"35","author":"Baldesi","year":"2009","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0009","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00133-06","article-title":"Interpretation of antibiotic concentration ratios measured in epithelial lining fluid","volume":"52","author":"Kiem","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0010","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1128\/AAC.36.6.1176","article-title":"Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance","volume":"36","author":"Baldwin","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0011","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jac\/31.3.331","article-title":"Pharmacokinetics of quinolones with special reference to the respiratory tree","volume":"31","author":"Decre","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0012","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1128\/AAC.35.10.1947","article-title":"Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning","volume":"35","author":"Nix","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0013","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ijantimicag.2010.08.013","article-title":"Antimicrobial chemotherapy and lung microdialysis: a review","volume":"36","author":"Dhanani","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0014","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s00134-013-3088-4","article-title":"Clinical implications of antibiotic pharmacokinetic principles in the critically ill","volume":"39","author":"Udy","year":"2013","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijantimicag.2011.10.015","article-title":"Comparative Activity of Carbapenem Testing (COMPACT) study in Germany","volume":"39","author":"Valenza","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0016","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcrc.2009.02.014","article-title":"Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia","volume":"25","author":"Nicasio","year":"2010","journal-title":"J Crit Care"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0017","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0018","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A new simplified acute physiology score (SAPS-II) based on a European North-American multicenter study","volume":"270","author":"Legall","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0019","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: Results of a multicenter, prospective study","volume":"26","author":"Vincent","year":"1998","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0020","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","article-title":"Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement","volume":"54","author":"Kanji","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0021","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/clpt.2014.131","article-title":"Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients","volume":"96","author":"Felton","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0022","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1365-2125.2003.01797.x","article-title":"Penetration of piperacillin and tazobactam into pneumonic human lung tissue measured by in vivo microdialysis","volume":"55","author":"Tomaselli","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0023","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s00134-004-2222-8","article-title":"Steady-state plasma and intrapulmonary concentrations of piperacillin\/tazobactam 4 g\/0.5 g administered to critically ill patients with severe nosocomial pneumonia","volume":"30","author":"Boselli","year":"2004","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0024","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1097\/CCM.0b013e318170ba21","article-title":"Alveolar concentrations of pipeyacillin\/tazobactam administered in continuous infusion to patients with ventilatoy-associated pneumonia","volume":"36","author":"Boselli","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0025","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1093\/jac\/dks246","article-title":"Intrapulmonary penetration of ceftolozane\/tazobactam and piperacillin\/tazobactam in healthy adult subjects","volume":"67","author":"Chandorkar","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0026","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00134-004-2171-2","article-title":"Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia","volume":"30","author":"Boselli","year":"2004","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0027","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1128\/AAC.04232-14","article-title":"Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia","volume":"59","author":"Cousson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0028","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/jac\/dkv170","article-title":"Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens","volume":"70","author":"Nicolau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0029","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/JCM.00893-06","article-title":"Effectiveness of cephalosporins in the sputum of patients with nosocomial bronchopneumonia","volume":"44","author":"Klekner","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0030","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1097\/01.CCM.0000069734.38738.C8","article-title":"Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia","volume":"31","author":"Boselli","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0031","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1128\/AAC.02755-15","article-title":"Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects","volume":"60","author":"Riccobene","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0032","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00134-006-0401-5","article-title":"Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia","volume":"32","author":"Boselli","year":"2006","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0033","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijantimicag.2005.08.015","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem","volume":"26","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0034","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1128\/AAC.48.6.2228-2232.2004","article-title":"Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis","volume":"48","author":"Tomaselli","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0035","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1128\/AAC.01330-10","article-title":"Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia","volume":"55","author":"Lodise","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0036","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jac\/dku354","article-title":"Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study","volume":"70","author":"Frippiat","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0037","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1128\/AAC.01713-15","article-title":"Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects","volume":"59","author":"Wenzler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0038","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.01578-08","article-title":"Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions","volume":"53","author":"Kikuchi","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0039","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01411-17","article-title":"Intrapulmonary pharmacokinetics of relebactam, a novel beta-lactamase inhibitor, dosed in combination with imipenem-cilastatin in healthy subjects","volume":"62","author":"Rizk","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0040","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00228-017-2327-y","article-title":"Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens","volume":"73","author":"Oesterreicher","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0041","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00134-007-0688-x","article-title":"Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients","volume":"33","author":"Boselli","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0042","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(99)70103-7","article-title":"Tobramycin penetration into epithelial lining fluid of patients with pneumonia","volume":"65","author":"Carcas","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0043","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1179\/joc.1995.7.4.363","article-title":"Tissue penetration and pulmonary disposition of tobramycin","volume":"7","author":"Mazzei","year":"1995","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0044","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1378\/chest.128.2.545","article-title":"Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia","volume":"128","author":"Panidis","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0045","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/AAC.39.1.264","article-title":"Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily","volume":"39","author":"Santre","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0046","doi-asserted-by":"crossref","DOI":"10.1177\/0885066618754784","article-title":"Evaluation of epithelial lining fluid concentration of amikacin in critically ill patients with ventilator-associated pneumonia","author":"Najmeddin","year":"2018","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0047","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jiac.2014.05.007","article-title":"Pharmacokinetics of arbekacin in bronchial epithelial lining fluid of healthy volunteers","volume":"20","author":"Funatsu","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0048","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.10-0463","article-title":"Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration","volume":"138","author":"Imberti","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0049","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1378\/chest.10-1860","article-title":"Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium","volume":"139","author":"Markou","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0050","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1128\/AAC.03510-14","article-title":"Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients","volume":"58","author":"Boisson","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0051","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkq070","article-title":"Extracellular concentrations of fosfomycin in lung tissue of septic patients","volume":"65","author":"Matzi","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0052","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijantimicag.2005.02.013","article-title":"Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline","volume":"25","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0053","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0054","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.02036-13","article-title":"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0055","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/01.CCM.0000150265.42067.4C","article-title":"Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia","volume":"33","author":"Boselli","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0056","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijantimicag.2006.03.022","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects","volume":"28","author":"Conte","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0057","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.47.8.2450-2457.2003","article-title":"Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults","volume":"47","author":"Rodvold","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0058","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1128\/AAC.48.2.638-640.2004","article-title":"Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia","volume":"48","author":"Leone","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0059","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, http:\/\/eucast.org; 2017 [accessed 05\/09\/2017]."},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0060","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0034-1398490","article-title":"Applying pharmacokinetic\/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development","volume":"36","author":"Abdul-Aziz","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0061","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1128\/AAC.00794-17","article-title":"Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae","volume":"61","author":"Cojutti","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0062","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","article-title":"Novel beta-lactamase inhibitors: unlocking their potential in therapy","volume":"77","author":"Wong","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0063","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1128\/AAC.00080-14","article-title":"Activities of ceftazidime and avibactam against \u03b2-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model","volume":"58","author":"Coleman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0064","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1128\/AAC.00851-12","article-title":"Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa","volume":"56","author":"Crandon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0066","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0067","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1164\/rccm.201011-1894OC","article-title":"Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa","volume":"184","author":"Lu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0068","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00134-011-2420-0","article-title":"BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia","volume":"38","author":"Niederman","year":"2012","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0069","doi-asserted-by":"crossref","DOI":"10.1186\/cc8206","article-title":"Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia","author":"Luyt","year":"2009","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0070","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00134-007-0935-1","article-title":"Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects","volume":"34","author":"Ehrmann","year":"2008","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0071","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1089\/jamp.2010.0860","article-title":"Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with gram-negative pneumonia and acute renal failure","volume":"24","author":"Luyt","year":"2011","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0072","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1089\/jamp.2013.1100","article-title":"A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow (R) inline nebulizer system in mechanically ventilated patients","volume":"27","author":"Montgomery","year":"2014","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0073","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1093\/jac\/dkw313","article-title":"Pharmacokinetics of high-dose nebulized amikacin in ventilated critically ill patients","volume":"71","author":"Petitcollin","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0074","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/jamp.2010.0859","article-title":"Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease","volume":"24","author":"Stass","year":"2011","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0075","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1093\/jac\/dkx167","article-title":"Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients","volume":"72","author":"Boisson","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0076","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00134-012-2628-7","article-title":"Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients","volume":"38","author":"Athanassa","year":"2012","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0077","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dky044","article-title":"Influence of diluent volume of colistimethate sodium on aerosol characteristics and pharmacokinetics in ventilator-associated pneumonia caused by MDR bacteria","author":"Bihan","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0078","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1128\/AAC.01314-10","article-title":"Optimization of Aminoglycoside Therapy","volume":"55","author":"Drusano","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0079","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria","volume":"43","author":"Kashuba","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0080","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1128\/AAC.00808-15","article-title":"Mucin binding reduces colistin antimicrobial activity","volume":"59","author":"Huang","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0081","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1128\/AAC.01650-15","article-title":"Extracellular DNA Acidifies Biofilms and Induces Aminoglycoside Resistance in Pseudomonas aeruginosa","volume":"60","author":"Wilton","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0082","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1128\/AAC.39.2.329","article-title":"Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin","volume":"39","author":"van 't Veen","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0083","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archsurg.134.12.1293","article-title":"Analysis of aminoglycosides in the treatment of gram-negative infections in surgical patients","volume":"134","author":"Crabtree","year":"1999","journal-title":"Arch Surg"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0084","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/ALN.0000000000001570","article-title":"Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis","volume":"126","author":"Sole-Lleonart","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0085","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jac\/dkv291","article-title":"Impact of 30 mg\/kg amikacin and 8 mg\/kg gentamicin on serum concentrations in critically ill patients with severe sepsis","volume":"71","author":"Roger","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0086","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijantimicag.2015.02.009","article-title":"Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations","volume":"46","author":"Roger","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0087","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00134-015-4114-5","article-title":"Aerosol therapy in intensive and intermediate care units: prospective observation of 2808 critically ill patients","volume":"42","author":"Ehrmann","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0088","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/jamp.2010.0816","article-title":"Delivery Efficacy of a Vibrating Mesh Nebulizer and a Jet Nebulizer under Different Configurations","volume":"23","author":"Pitance","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0089","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1183\/09031936.97.10040905","article-title":"Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation","volume":"10","author":"Harvey","year":"1997","journal-title":"Eur Resp J"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13613-016-0140-x","article-title":"Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient","volume":"6","author":"Bassetti","year":"2016","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0091","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4187\/respcare.10550837","article-title":"Evaluation of aerosol generator devices at 3 locations in humidified and non-humidified circuits during adult mechanical ventilation","volume":"55","author":"Ari","year":"2010","journal-title":"Respir Care"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0092","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13054-016-1448-5","article-title":"Fundamentals of aerosol therapy in critical care","volume":"20","author":"Dhanani","year":"2016","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0093","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/CCM.0000000000002695","article-title":"Nebulized versus IV amikacin as adjunctive antibiotic for hospital and ventilator-acquired pneumonia postcardiac surgeries: a randomized controlled trial","volume":"46","author":"Hassan","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0094","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4103\/0366-6999.205846","article-title":"Aerosolized amikacin as adjunctive therapy of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a single-center randomized controlled trial","volume":"130","author":"Liu","year":"2017","journal-title":"Chin Med J"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0095","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.chest.2016.11.026","article-title":"A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia IASIS Trial","volume":"151","author":"Kollef","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0096","first-page":"1","article-title":"A prospective, randomized, controlled trial to evaluate the safety and efficacy of nebulized amikacin as adjunctive therapy in hospital acquired and ventilator associated pneumonia in surgical ICUs","volume":"193","author":"Hassan","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0097","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1164\/rccm.201312-2161OC","article-title":"Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit","volume":"189","author":"Palmer","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0098","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/CCM.0b013e31817c0f9e","article-title":"Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit","volume":"36","author":"Palmer","year":"2008","journal-title":"Crit Care Med"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2018.11.011_bib0099","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1086\/426191","article-title":"Quinolones for treatment of nosocomial pneumonia: a meta-analysis","volume":"40","author":"Shorr","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ijantimicag.2015.09.011","article-title":"Intravenous combined with aerosolised polymyxin versus intravenous polymyxin alone in the treatment of pneumonia caused by multidrug-resistant pathogens: a systematic review and meta-analysis","volume":"46","author":"Liu","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0101","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1128\/AAC.00903-09","article-title":"Pharmacokinetic\/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model","volume":"54","author":"Bergen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0102","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01615-10","article-title":"Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline","volume":"56","author":"Bhavnani","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0103","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1128\/AAC.01253-10","article-title":"In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase","volume":"55","author":"Wiskirchen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0104","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0105","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0106","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1183\/09031936.04.00106803","article-title":"Comparison of 99mTc-DTPA and urea for measuring cefepime concentrations in epithelial lining fluid","volume":"24","author":"Bayat","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0107","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1183\/09031936.93.02060561","article-title":"Technical recommendations and guidelines for bronchoalveolar lavage (BAL)","volume":"2","author":"Klech","year":"1989","journal-title":"Eur Resp J"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0108","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1164\/ajrccm.160.3.9811049","article-title":"Validity of markers of dilution in small volume lung lavage","volume":"160","author":"Dargaville","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0301-5629(99)00118-0","article-title":"Reactive pulmonary artery vasoconstriction in pulmonary consolidation evaluated by color Doppler ultrasonography","volume":"26","author":"Yuan","year":"2000","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0110","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.burns.2012.02.019","article-title":"Pulmonary microvascular hyperpermeability and expression of vascular endothelial growth factor in smoke inhalation-and pneumonia-induced acute lung injury","volume":"38","author":"Lange","year":"2012","journal-title":"Burns"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0111","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1164\/arrd.1983.127.1.39","article-title":"Endobronchial pH. Relevance of aminoglycoside activity in gram-negative bacillary pneumonia","volume":"127","author":"Bodem","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0112","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1164\/rccm.201709-1819OC","article-title":"Excess mucin impairs subglottic epithelial host defense in mechanically ventilated patients","volume":"198","author":"Powell","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.11.011_bib0113","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2958.2005.04941.x","article-title":"Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance","volume":"59","author":"Landry","year":"2006","journal-title":"Mol Microbiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:22:13Z","timestamp":1775280133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918303364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0924857918303364"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.011","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}